Korro Bio, Inc. KRRO 深 沪
等待开盘 05-12 09:30:00 美东时间
11.96
-0.160
-1.32%
华盛通- 最 高13.65
- 今 开12.12
- 成交量 3.86万股
- 最 低 11.61
- 昨 收 12.12
- 总市值 0
- 52周最高 55.89
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 5.2044
- 委 比 -1.52%
- 总股本 --
- 历史最高 98.00
- 量 比 0.68
- 振 幅 16.83%
- 历史最低 0.183
- 每 手 1
- 风险率 11.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Korro Bio Secures ~$85M PIPE Financing Via Subscription Agreement
Financing led by new investor Venrock Healthcare Capital Partners, with participation from new and existing investors Proceeds support the achievement of value inflection points for multiple RNA editing programs
03-09 19:36
William Blair Upgrades Korro Bio to Outperform
William Blair analyst Myles Minter upgrades Korro Bio (NASDAQ:KRRO) from Market Perform to Outperform.
02-17 23:23
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers ENvue Medical (NASDAQ:FEED) stock rose 80.4% to $4.15 during Thursday'...
01-30 01:05
Korro Bio Early Trial Results Fall Short; Stock Hits New Low
Korro Bio shares drop after KRRO-110 trial in AATD misses protein goals; company cuts 34% of staff and shifts focus to liver-targeted programs.
2025-11-14 03:26
Dow Dips Over 400 Points; JD.com Posts Upbeat Q3 Results
U.S. stocks traded lower midway through trading, with the Nasdaq Composite fall...
2025-11-14 01:03
HC Wainwright & Co. Downgrades Korro Bio to Neutral
HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Korro Bio (NASDAQ:KRRO) from Buy to Neutral.
2025-11-13 20:39
Why Cisco Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Shares of Cisco Systems, Inc. (NASDAQ:CSCO) rose sharply in pre-market trading ...
2025-11-13 18:16
Korro Bio Announces Collaboration With Novo Nordisk To Develop Two Therapeutic Candidates, Leveraging Korro's Proprietary OPERA Platform To Enable Its Oligonucleotide-Directed RNA Edits Into Two Undisclosed Targets; Initially For Cardiometabolic Diseases; Total Deal Value Of Up To $530M In Upfront, Development, And Commercial Milestone Payments, In Addition To Tiered Royalties And R&D Funding
Partnership leverages Korro's proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits into two undisclosed targets; initially for cardiometabolic diseases Total deal value of up to $530 million
2024-09-16 20:12
